Operator

Good morning, and welcome to today's conference call regarding the merger agreement between InMed Pharmaceuticals and Mentari Therapeutics. [Operator Instructions] Please be advised the call is being recorded and will be available for replay on the InMed website. Now I'd like to turn the call over to Colin Clancy, Vice President, Investor Relations and Corporate Communications, InMed Pharmaceuticals. Please proceed, sir.

Colin Clancy
VP of Investor Relations & Corporate Communications

Thank you, operator, and good morning, everyone. Before we continue, I would like to remind attendees that today's call may include forward-looking statements. These statements reflect the expectations and beliefs of both InMed Pharmaceuticals and Mentari Therapeutics regarding the potential outcomes of the merger and the future business plans. They may include projections on clinical development time lines, potential differentiation from other therapies, expected financial resources following the completion of the transaction, business milestones, market sizes and the potential benefit for shareholders. It is important to understand that these forward-looking statements are subject to risks and uncertainties. These risks include, but are not limited to, the ability to close the merger, achieve clinical milestones, maintain adequate funding and the conditions precedent to completion of the merger, including the receipt of required regulatory approvals and the ability to close the merger.

Our actual results may differ materially from expectations. For a discussion of risks and uncertainties, please review the descriptions included under the heading Risk Factors and Business in InMed's most recent annual report on Form 10-K filed with the SEC as well as other SEC filings made by InMed from time to time. In addition, InMed intends to file a